Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors

Area of Science:

• Immunology
• Nanotechnology
• Oncology

Background:

• Effective cancer vaccines require robust humoral and cellular immune responses, particularly antigen-specific cytotoxic T cells.
• Current vaccine strategies often face challenges with insufficient immunogenicity, necessitating adjuvants and carrier platforms for stability and retention.
• Developing potent and stable cancer vaccines remains a critical area of research in immunotherapy.

Purpose of the Study:

• To introduce a novel pH-responsive nanogel platform as a safe, two-component antitumor vaccine for intravenous application.
• To evaluate the immunogenicity and efficacy of the nanovaccine platform in eliciting antigen-specific immune responses and reducing tumor growth.
• To explore the potential of functionalized nanogels for developing customized and potent nanovaccines.

Main Methods:

• Development of a pH-responsive nanogel platform enabling covalent attachment of a model antigen (ovalbumin) and an immune adjuvant (TLR7/8 agonist).
• In vitro and in vivo evaluation of the nanovaccine's safety and immunogenicity, including T and B cell responses.
• Assessment of the nanovaccine's efficacy in prophylactic and therapeutic studies against tumors expressing ovalbumin.

Main Results:

• The two-component nanovaccine demonstrated robust in vitro and in vivo immune responses, outperforming mixtures of individual components.
• Intravenous application of the nanovaccine was found to be safe.
• Prophylactic and therapeutic studies showed significant antigen-specific tumor growth reduction in models with ovalbumin-expressing tumors.

Conclusions:

• The pH-responsive nanogel platform serves as a potent two-component antitumor vaccine with promising safety for intravenous administration.
• The nanovaccine elicits superior antigen-specific T and B cell responses compared to individual component mixtures.
• This nanogel platform offers versatile functionalization opportunities for the development of highly customized and effective nanovaccines against cancer.